RECOVERY & TISSUE REPAIR / FAQ
Questions From the Literature
Precise, citation-anchored answers to the questions readers most often bring to the Wolverine blend, BPC-157, and TB-500.
What is the Wolverine peptide blend?
Wolverine is a name used in the research-peptide community for a two-component stack pairing BPC-157 and TB-500. The rationale is that BPC-157 drives angiogenesis — new blood-vessel growth into injured tissue via the VEGFR2-Akt-eNOS pathway [4] — while TB-500 regulates actin dynamics, the cytoskeletal mechanism cells use to migrate toward a wound [6]. The theory is that these mechanisms complement rather than overlap each other. What the community calls Wolverine does not have a formal chemical identity, no controlled study has tested the combination, and its "synergy" is a hypothesis, not a finding [1][2].
What is BPC-157 and TB-500?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a cytoprotective protein in human gastric juice. TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of a natural protein called thymosin beta-4. BPC-157 is studied primarily for its pro-angiogenic (vessel-growing) effects in animal models of tendon, gut, and vascular injury [4][7]. TB-500 is studied in the context of actin regulation and cell migration; its parent protein thymosin beta-4 has been examined in wound, cardiac, and CNS repair models [5][6]. Neither is an approved drug and both are banned in sport [1].
What is the BPC-157 and TB-500 blend used for in research?
As a formal matter, the combination is not used in peer-reviewed research — no published study has examined BPC-157 and TB-500 given together [2]. In the research-peptide community, the Wolverine pairing is most often used with the goal of accelerating recovery from tendon, ligament, and soft-tissue injuries, based on the presumed complementarity of the two individual peptides' mechanisms. A 2026 Sports Medicine review of unapproved peptides for musculoskeletal injury and athletic performance notes that many such peptides show animal-model promise but scarce human safety data [1]. Individual component uses are described on the BPC-157 and TB-500 pages.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The conceptual justification is mechanistic complementarity: BPC-157 is theorized to build new blood vessels into an injury (angiogenesis, via VEGFR2-Akt-eNOS) while TB-500 / thymosin beta-4 is theorized to mobilize the cells that need to fill and organize the repair scaffold (actin sequestration driving cell migration) [4][5][6]. These two actions are described as largely non-overlapping, which is the basis for combining them. That mechanistic rationale is coherent; the problem is that no controlled study has confirmed whether the combination actually outperforms either peptide alone, or defined what combined dosing and safety look like [1][2].
What does BPC-157 do in the body?
In animal models, BPC-157 is described as a cytoprotective and regenerative peptide whose effects are most consistently tied to angiogenesis — promoting new blood-vessel growth by up-regulating the VEGFR2 receptor and activating the downstream Akt-eNOS pathway [4]. It has accelerated healing in rat models of gastric ulcers [10] and fully transected Achilles tendon [7], and it engages cell-migration pathways and the growth-hormone receptor in tendon fibroblasts [7]. Almost all of this is preclinical; human evidence is limited to three small pilot studies [3].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and does not act as one. It is a synthetic fifteen-amino-acid peptide derived from gastric juice. The connection point that causes confusion: in tendon cell work, BPC-157 has been reported to sensitize the growth-hormone receptor, potentially amplifying the effect of the body's own growth hormone [7]. Making a receptor more responsive is not the same as being a growth hormone. BPC-157 does not substitute for, mimic, or act as growth hormone.
Does BPC-157 work immediately?
The intact peptide clears from the bloodstream quickly. Pharmacokinetic work in rats and beagle dogs found an elimination half-life of under 30 minutes, with rapid breakdown into small fragments that re-enter amino-acid metabolism [9]. A short half-life means the intact molecule does not linger. Whether any healing effect begins quickly is a separate question from pharmacokinetics; the published healing data are from animal studies measured over days to weeks [7]. This desk does not advise on use, timing, or protocols.
Does BPC-157 damage the liver?
The available data do not indicate liver harm, but the dataset is very small. In the 2025 first-in-human intravenous safety pilot — BPC-157 up to 20 mg in two healthy adults — no measurable changes in hepatic biomarkers were observed, alongside no cardiac, renal, thyroid, or glucose changes and no adverse events [8]. That is reassuring within a sample of two people in a safety pilot, not a dedicated liver-safety study. A 2025 narrative review stresses that without large-scale, long-term human data, the overall safety profile of BPC-157 remains genuinely unknown [3].
What is TB-500?
TB-500 is a short synthetic peptide — seven amino acids — with the sequence Ac-LKKTETQ (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln). It is derived from residues 17–23 of thymosin beta-4 (Tβ4), which is the conserved actin-binding region of the beta-thymosin family [6]. In commerce and anti-doping science, "TB-500" denotes this short fragment; in the published effectiveness literature, most studies used full-length Tβ4, a 43-amino-acid protein substantially larger than the fragment [1][5]. The two are distinct molecules and their effects should not be assumed to be identical.
What does TB-500 stand for and what does TB stand for in TB-500?
"TB" refers to thymosin beta — specifically thymosin beta-4 (Tβ4), the natural protein TB-500 is derived from. The 500 designation comes from its commercial and research context as a fragment preparation. TB-500 itself is the Ac-LKKTETQ heptapeptide corresponding to residues 17–23 of Tβ4, which is the actin-binding region of the protein [6]. An important nuance: most published efficacy research is conducted with full-length thymosin beta-4, not this fragment, so the name points at the fragment while much of its cited research used the whole protein [1].
What is TB-500 used for in research?
In research, TB-500 (and more often, full-length thymosin beta-4) is studied in the context of tissue repair driven by actin regulation: cell migration, angiogenesis, reduced scarring, and anti-inflammatory signaling in dermal wound, corneal, cardiac, and CNS injury models [5]. A Phase 1 human study of full-length Tβ4 in 40 volunteers focused on safety and pharmacokinetics [12], and a rat embolic-stroke study examined neurological dose-response [11]. There are no completed controlled clinical trials of the TB-500 heptapeptide fragment for any indication [1].
Does TB-500 work for muscle tears and recovery from exercise?
There is no controlled human evidence that the TB-500 fragment helps muscle tears or exercise recovery. The mechanistic rationale comes from thymosin beta-4's role in actin regulation, cell migration, and tissue repair [5]. A 2026 Sports Medicine review of unapproved musculoskeletal peptides concluded that favorable animal results have not been matched by rigorous human safety or efficacy data, and that these compounds operate largely outside regulatory oversight [1]. An animal result worth noting: in a muscular-dystrophy mouse model, chronic Tβ4 increased regenerating fibers but did not improve muscle strength, cardiac function, or fibrosis [5]. TB-500 is banned in sport [1].